. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2016 Jul 2;78(2):427–432. doi: 10.1007/s00280-016-3087-6

Table 3.

Incidence of adverse events in patients on erlotinib with and without concurrent acid suppression (PPI/H₂RA)

		n	Rash n (%)	P^†	Diarrhea n (%)	P^†	Rash & diarrhea n (%)	P^†
Concurrent PPI	Erlotinib alone	52	37 (71.5%)	0.21	29 (55.7%)	0.52	23 (44.2%)	0.84
Concurrent PPI	Erlotinib + acid- suppression	24	20 (83.3%)	0.21	11 (45.8%)	0.52	11 (45.8%)	0.84
Sex	Male	33	28 (84.8%)	0.052	17 (51.5%)	0.98	16 (48.5%)	0.43
Sex	Female	43	28 (65.1%)	0.052	22 (51.2%)	0.98	17 (39.5%)	0.43
Cancer type	Lung	69	51 (73.9%)	0.89	35 (50.7%)	0.30	29 (42.0%)	0.99
Cancer type	Not lung	7	5 (71.4%)	0.89	5 (71.4%)	0.30	4 (57.1%)	0.99
Age^*	Age > 66 years	40	27 (67.5%)	0.20	23 (57.5%)	0.26	17 (42.5%)	0.86
Age^*	Age ≤ 66 years	36	29 (80.6%)	0.20	16 (44.4%)	0.26	16 (44.4%)	0.86

Abbreviations: PPI: proton pump inhibitor; H₂RA: histamine-2 receptor antagonist.

Median age is 66 years old

^†

Calculated using Fisher’s exact test